• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    M

    Minnesota Ovarian Cancer Alliance

    EST. 1999
    10论文总数
    132引用总数

    The Minnesota Ovarian Cancer Alliance is an organization for women with ovarian cancer in the state of Minnesota. The organization raises public awareness of ovarian cancer and helps to fund medical research. The Minnesota Ovarian Cancer Alliance (MOCA) was established in 1999..

    论文量&引用量时间轴

    机构学者

    论文(10)

    年份
    起
    –
    止
    排序
    1Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical Trial.
    Karen H Lu,Barbara M Norquist,Gary B Chisholm,Christine B Peterson, Kara C Long Roche,Jamie N Bakkum-Gamez,Iris L Romero, Colleen Feltmate,Douglas A Levine,Sarah Kim,Andrea R Hagemann,Jeanne Carter,

    Importance:Risk-reducing salpingo-oophorectomy (RRSO) is an effective option to prevent ovarian cancer in high-risk individuals, but adverse effects from premature menopause are a barrier to uptake. Interval salpingectomy with delayed oophorectomy (ISDO) may be an effective alternative. Objective:To evaluate the association of ISDO vs RRSO and sexual function and menopausal symptoms. Design, Setting, and Participants:This prospective, multicenter, nonrandomized (patient preference) clinical trial was performed among Women Choosing Surgical Prevention participants with a pathogenic or likely pathogenic germline variant conferring an increased risk for ovarian cancer. Patients from 9 US centers were enrolled from June 2, 2016, to October 28, 2020; chose ISDO or RRSO; and were followed up for 24 months. The analysis was performed on November 13, 2024. Interventions:Participant-selected RRSO or ISDO. Main Outcomes and Measures:Changes in sexual function and menopausal symptoms from baseline to 6, 12, and 24 months. Inverse probability weighting was applied to achieve covariate balance across groups. Results:The analytic sample included 334 female participants (mean [95% CI] age at consent, 39.2 [38.7-.9.7] years) who underwent RRSO (n = 165) or ISDO (n = 169) and completed 6-month questionnaires. Significantly more participants experienced clinically meaningful worsening of sexual function at 6 months compared with baseline after RRSO vs ISDO (33.1% [39 of 118] vs 16.8% [17 of 101], respectively; odds ratio, 2.00 [95% CI, 1.20-3.35]) and at 12 months (39.2% [38 of 97] vs 18.3% [17 of 93], respectively; odds ratio, 1.69 [95% CI, 1.09-2.63]). This finding was no longer significant at 24 months. When restricted to the RRSO group who took hormone replacement therapy, there was no significant worsening of total sexual function scores or menopausal symptoms compared with baseline. No interval ovarian cancers were reported. Conclusions and Relevance:This nonrandomized clinical trial comparing RRSO with ISDO found that ISDO was less likely to impair sexual function, which addresses an important barrier to surgical prevention in high-risk patients in premenopause. After RRSO, use of hormone replacement therapy mitigated menopausal symptoms and prevented decline in sexual function. More information is needed about the safety of ISDO. Trial Registration:ClinicalTrials.gov Identifier: NCT02760849.

    2026JAMA network open(2026)
    引用
    AI阅读
    加入学术空间
    2Sexual Function and Menopausal Symptoms among Patients at High Risk of Ovarian Carcinoma Undergoing Interval Salpingectomy or Risk-Reducing Salpingo-Oophorectomy in the Prospective Multicenter WISP Trial
    Barbara Norquist,Denise Nebgen,Kara Long Roche,Jamie Bakkum-Gamez,Iris Romero,Colleen Feltmate,Douglas Levine,Sarah Kim,Andrea Hagemann,Jeanne Carter,Jamie Crase,Kathleen Gavin,
    2024GYNECOLOGIC ONCOLOGY(2024)
    引用
    AI阅读
    加入学术空间
    3Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial.
    Elizabeth M. Swisher,Nadine Rayes,Deborah Bowen,Christine B. Peterson,Barbara M. Norquist,Tara Coffin,Kathleen Gavin,Deborah Polinsky,Jamie Crase,Jamie N. Bakkum-Gamez,Stephanie V. Blank,Mark F. Munsell,

    Importance:Requiring personalized genetic counseling may introduce barriers to cancer risk assessment, but it is unknown whether omitting counseling could increase distress. Objective:To assess whether omitting pretest and/or posttest genetic counseling would increase distress during remote testing. Design, Setting, and Participants:Making Genetic Testing Accessible (MAGENTA) was a 4-arm, randomized noninferiority trial testing the effects of individualized pretest and/or posttest genetic counseling on participant distress 3 and 12 months posttest. Participants were recruited via social and traditional media, and enrollment occurred between April 27, 2017, and September 29, 2020. Participants were women aged 30 years or older, English-speaking, US residents, and had access to the internet and a health care professional. Previous cancer genetic testing or counseling was exclusionary. In the family history cohort, participants had a personal or family history of breast or ovarian cancer. In the familial pathogenic variant (PV) cohort, participants reported 1 biological relative with a PV in an actionable cancer susceptibility gene. Data analysis was performed between December 13, 2020, and May 31, 2023. Intervention:Participants completed baseline questionnaires, watched an educational video, and were randomized to 1 of 4 arms: the control arm with pretest and/or posttest genetic counseling, or 1 of 3 study arms without pretest and posttest counseling. Genetic counseling was provided by phone appointments and testing was done using home-delivered saliva kits. Main Outcomes and Measures:The primary outcome was participant distress measured by the Impact of Event Scale 3 months after receiving the results. Secondary outcomes included completion of testing, anxiety, depression, and decisional regret. Results:A total of 3839 women (median age, 44 years [range 22-91 years]), most of whom were non-Hispanic White and college educated, were randomized, 3125 in the family history and 714 in the familial PV cohorts. In the primary analysis in the family history cohort, all experimental arms were noninferior for distress at 3 months. There were no statistically significant differences in anxiety, depression, or decisional regret at 3 months. The highest completion rates were seen in the 2 arms without pretest counseling. Conclusions and Relevance:In the MAGENTA clinical trial, omitting individualized pretest counseling for all participants and posttest counseling for those without PV during remote genetic testing was not inferior with regard to posttest distress, providing an alternative care model for genetic risk assessment. Trial Registration:ClinicalTrials.gov Identifier: NCT02993068.

    2023JAMA ONCOLOGY(2023)引用:36
    引用
    AI阅读
    加入学术空间
    4Using Social Media to Facilitate Communication about Women’s Testing: Tool Validation Study
    Tara Coffin,Deborah Bowen,Karen Lu,Elizabeth M. Swisher,Nadine Rayes,Barbara Norquist,Stephanie Blank,Douglas A. Levine,Jamie Nadine Bakkum-Gamez,Gini F. Fleming,Olufunmilayo Olopade,Iris Romero,

    Background Strong participant recruitment practices are critical to public health research but are difficult to achieve. Traditional recruitment practices are often time consuming, costly, and fail to adequately target difficult-to-reach populations. Social media platforms such as Facebook are well-positioned to address this area of need, enabling researchers to leverage existing social networks and deliver targeted information. The MAGENTA (Making Genetic Testing Accessible) study aimed to improve the availability of genetic testing for hereditary cancer susceptibility in at-risk individuals through the use of a web-based communication system along with social media advertisements to improve reach. Objective This paper is aimed to evaluate the effectiveness of Facebook as an outreach tool for targeting women aged ≥30 years for recruitment in the MAGENTA study. Methods We designed and implemented paid and unpaid social media posts with ongoing assessment as a primary means of research participant recruitment in collaboration with patient advocates. Facebook analytics were used to assess the effectiveness of paid and unpaid outreach efforts. Results Over the course of the reported recruitment period, Facebook materials had a reach of 407,769 people and 57,248 (14.04%) instances of engagement, indicating that approximately 14.04% of people who saw information about the study on Facebook engaged with the content. Paid advertisements had a total reach of 373,682. Among those reached, just <15% (54,117/373,682, 14.48%) engaged with the page content. Unpaid posts published on the MAGENTA Facebook page resulted in a total of 34,087 reach and 3131 instances of engagement, indicating that around 9.19% (3131/34,087) of people who saw unpaid posts engaged. Women aged ≥65 years reported the best response rate, with approximately 43.95% (15,124/34,410) of reaches translating to engagement. Among the participants who completed the eligibility questionnaire, 27.44% (3837/13,983) had heard about the study through social media or another webpage. Conclusions Facebook is a useful way of enhancing clinical trial recruitment of women aged ≥30 years who have a potentially increased risk for ovarian cancer by promoting news stories over social media, collaborating with patient advocacy groups, and running paid and unpaid campaigns. Trial Registration ClinicalTrials.gov NCT02993068; https://clinicaltrials.gov/ct2/show/NCT02993068

    2022JMIR FORMATIVE RESEARCH(2022)引用:6
    引用
    AI阅读
    加入学术空间
    5An Accessible Communication System for Population-Based Genetic Testing: Development and Usability Study
    Tara Coffin,Deborah Bowen,Elizabeth Swisher,Karen Lu,Nadine Rayes,Barbara Norquist,Stephanie Blank, Douglas Levine,Jamie Bakkum-Gamez,Gini Fleming,Olufunmilayo Olopade,Alan D'Andrea,

    Background: Genetic testing uptake is low, despite the well-established connection between pathogenic variants in certain cancer-linked susceptibility genes and ovarian cancer risk. Given that most major insurers cover genetic testing for those with a family history suggestive of hereditary cancer, the issue may lie in access to genetic testing. Remotely accessible web-based communication systems may improve awareness, and uptake, of genetic testing services. Objective: This study aims to present the development and formative evaluation of the multistep web-based communication system required to support the implementation of, and access to, genetic testing. Methods: While designing the multistep web-based communication system, we considered various barriers and facilitators to genetic testing, guided by dimensions of accessibility. In addition to conducting usability testing, we performed ongoing assessments focusing on the function of the web-based system and participant response rates, with the goal of continuing to make modifications to the web-based communication system as it is in use. Results: The combined approach of usability testing and expert user experience consultation resulted in several modifications to the multistep web-based communication system, including changes that related to imagery and content, web accessibility, and general organization of the web-based system. All recommendations were made with the goal of improving the overall accessibility of the web-based communication system. Conclusions: A multistep web-based communication system appears to be an effective way to address many potential barriers to access, which may otherwise make genetic testing difficult for at-risk individuals to participate in. Importantly, some dimensions of access were easy to assess before study recruitment, but other aspects of the communication system required ongoing assessment during the implementation process of the Making Genetic Testing Accessible study.

    2022JMIR FORMATIVE RESEARCH(2022)引用:3
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 10 篇论文

    合作机构(30)

    华盛顿大学合作论文 7
    芝加哥大学合作论文 6
    德州大學安德森癌症中心合作论文 5
    纽约大学朗格尼健康学院合作论文 3
    宾夕法尼亚大学合作论文 2
    Singapore-HUJ Alliance for Research and Enterprise合作论文 2
    纪念斯隆凯特琳癌症中心合作论文 2
    The University of Texas MD Anderson Cancer Center,The University of Texas System合作论文 2
    圣路易斯华盛顿大学合作论文 2
    布莱根妇女医院合作论文 1

    机构统计